Evidence map›Paper›PMID 38094666›Full record

ArticleOpen forum infectious diseases2023

Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant.

Johan Courjon, Vera Portillo, Sabine Yerly, Pauline Vetter, Manuel Schibler, Maria Mappoura, Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Christian van Delden and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Johan CourjonDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-0445-5104
Vera PortilloDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
Sabine YerlyLaboratory of Virology, Division of Laboratory Medicine, University Hospital of Geneva, Geneva, Switzerland.
Pauline VetterDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-9902-5069
Manuel SchiblerDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
Maria MappouraDivision of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Sarah MorinDivision of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Federica GiannottiGeneva Center for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.
Anne-Claire MamezDivision of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Christian van DeldenDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
Laurent KaiserDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.
Yves ChalandonDivision of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-9341-8104
Stavroula Masouridi-LevratDivision of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Dionysios NeofytosDivision of Infectious Diseases, University Hospital of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0001-6970-2869
University Hospital of Geneva · CHUniversity of Geneva · CHInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Among 292 recipients of allogeneic hematopoietic cell transplant (2018-2022), 64 (21.9%) tested positive for anti-hepatitis E virus (HEV) immunoglobulin G. Among 208 recipients tested by plasma/serum HEV polymerase chain reaction (2012-2022), 3 (1.4%) primary HEV infections were diagnosed; in 1 patient, plasma HEV polymerase chain reaction relapsed positive for 100 days. HEV infection remains rare albeit associated with persistent viral replication.

Indexed as

acute hepatitis Eallogeneic hematopoietic cell transplantationhepatitis E virusimmunosuppressionseroprevalance

Identifiers

PMID38094666
PMCPMC10716736
OpenAlexW4388994131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.